These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 20070407

  • 21. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.
    Winston A, Bloch M, Carr A, Amin J, Mallon PW, Ray J, Marriott D, Cooper DA, Emery S.
    J Antimicrob Chemother; 2005 Aug; 56(2):380-7. PubMed ID: 15996972
    [Abstract] [Full Text] [Related]

  • 22. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.
    Fabbiani M, Di Giambenedetto S, Bracciale L, Bacarelli A, Ragazzoni E, Cauda R, Navarra P, De Luca A.
    J Antimicrob Chemother; 2009 Jul; 64(1):109-17. PubMed ID: 19398461
    [Abstract] [Full Text] [Related]

  • 23. Predictors of virological response to atazanavir in protease inhibitor-experienced patients.
    Barrios A, Rendón AL, Gallego O, Martín-Carbonero L, Valer L, Ríos P, Maida I, García-Benayas T, Jiménez-Nácher I, González-Lahoz J, Soriano V.
    HIV Clin Trials; 2004 Jul; 5(4):201-5. PubMed ID: 15472794
    [Abstract] [Full Text] [Related]

  • 24. Factors predictive of virological failure on atazanavir in 310 HIV-infected patients.
    Lescure FX, Poirier JM, Meynard JL, Guiard-Schmid JB, Zouai O, Bonnard P, Slama L, Amiel C, Girard PM, Pialoux G.
    AIDS; 2010 Jun 19; 24(10):1593-5. PubMed ID: 20539093
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
    Rodríguez-Nóvoa S, Morello J, Barreiro P, Maida I, García-Gascó P, Vispo E, González-Pardo G, Parra A, Jiménez-Nácher I, Soriano V.
    AIDS Res Hum Retroviruses; 2008 Jun 19; 24(6):821-5. PubMed ID: 18507524
    [Abstract] [Full Text] [Related]

  • 27. Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children.
    Larru B, de Mendoza C, Bellón JM, de José MI, Mellado MJ, Soriano V, Muñoz-Fernandez MA, Ramos JT.
    BMC Infect Dis; 2007 Jun 10; 7():55. PubMed ID: 17559687
    [Abstract] [Full Text] [Related]

  • 28. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
    Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Wirtz V, Rightmire A, Odeshoo L, McLaren C.
    AIDS; 2006 Mar 21; 20(5):711-8. PubMed ID: 16514301
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.
    Colombo S, Buclin T, Cavassini M, Décosterd LA, Telenti A, Biollaz J, Csajka C.
    Antimicrob Agents Chemother; 2006 Nov 21; 50(11):3801-8. PubMed ID: 16940065
    [Abstract] [Full Text] [Related]

  • 33. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
    Piketty C, Gérard L, Chazallon C, Marcelin AG, Clavel F, Taburet AM, Calvez V, Madelaine-Chambrin I, Molina JM, Aboulker JP, Girard PM, Agence Nationale de Recherche sur le SIDA 107-Puzzle 2 Study Group.
    Antivir Ther; 2006 Nov 21; 11(2):213-21. PubMed ID: 16640102
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
    Gianotti N, Galli L, Danise A, Hasson H, Boeri E, Lazzarin A, Castagna A.
    J Med Virol; 2006 Dec 21; 78(12):1537-41. PubMed ID: 17063520
    [Abstract] [Full Text] [Related]

  • 36. Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy.
    Lichterfeld M, Wöhrmann A, Schmeisser N, Fätkenheuer G, Salzberger B, Wyen C, Schmitz K, Sauerbruch T, Rockstroh JK.
    Eur J Med Res; 2003 Feb 21; 8(2):56-60. PubMed ID: 12626282
    [Abstract] [Full Text] [Related]

  • 37. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
    Macassa E, Delaugerre C, Teglas JP, Jullien V, Tréluyer JM, Veber F, Rouzioux C, Blanche S.
    Pediatr Infect Dis J; 2006 Sep 21; 25(9):809-14. PubMed ID: 16940839
    [Abstract] [Full Text] [Related]

  • 38. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.
    Castagna A, Gianotti N, Galli L, Danise A, Hasson H, Boeri E, Hoetelmans R, Nauwelaers D, Lazzarin A.
    Antivir Ther; 2004 Aug 21; 9(4):537-43. PubMed ID: 15456085
    [Abstract] [Full Text] [Related]

  • 39. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.
    Tinago W, O'Halloran JA, O'Halloran RM, Macken A, Lambert JS, Sheehan GJ, Mallon PW.
    HIV Med; 2014 Apr 21; 15(4):224-32. PubMed ID: 24215370
    [Abstract] [Full Text] [Related]

  • 40. Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients.
    Bonora S, Gonzalez de Requena D, D'Avolio A, Calcagno A, Tettoni M, Siccardi M, Baietto L, Simiele M, Trentini L, Di Perri G.
    Antivir Ther; 2011 Apr 21; 16(4):499-504. PubMed ID: 21685537
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.